我们从临床试验中学到了正确的东西吗？ - Suppr

Suppr

超能文献

Do we learn the right things from clinical trials?

作者信息

Garattini Silvio, Bertele' Vittorio

机构信息

Mario Negri Institute for Pharmacological Research, Milan, Italy.

出版信息

Eur J Clin Pharmacol. 2008 Feb;64(2):115-25. doi: 10.1007/s00228-007-0411-4. Epub 2008 Jan 29.

DOI:10.1007/s00228-007-0411-4

PMID:18228013

Abstract

摘要

相似文献

Do we learn the right things from clinical trials?

Eur J Clin Pharmacol. 2008 Feb;64(2):115-25. doi: 10.1007/s00228-007-0411-4. Epub 2008 Jan 29.

Social, cultural and ethical aspects of drug use -- changes over 40 years: a personal look back.

Eur J Clin Pharmacol. 2008 Feb;64(2):107-14. doi: 10.1007/s00228-007-0429-7. Epub 2008 Jan 3.

Historical perspective and evolving concerns for human research.

Cancer Treat Res. 2007;132:1-10. doi: 10.1007/978-0-387-33225-3_1.

The history and development of N-of-1 trials.

J R Soc Med. 2017 Aug;110(8):330-340. doi: 10.1177/0141076817721131.

Show drugs work before selling them.

Nature. 2017 Mar 8;543(7644):174-175. doi: 10.1038/543174a.

Commentary for history special issue of Research Synthesis Methods.

Res Synth Methods. 2015 Sep;6(3):268-71. doi: 10.1002/jrsm.1144. Epub 2015 Jun 10.

Form meets function: A commentary on meta-analytic history.

Res Synth Methods. 2015 Sep;6(3):290-2. doi: 10.1002/jrsm.1141. Epub 2015 Jun 10.

The therapeutic test: an ancient malady in the 21st century.

Ann Pharmacother. 2010 Sep;44(9):1471-7. doi: 10.1345/aph.1P244. Epub 2010 Aug 17.

Seeking medicine for the soul.

R I Med J (2013). 2013 Jul 1;96(7):11-2.

Outcomes and endpoints in trials of cancer treatment: the past, present, and future.

Lancet Oncol. 2015 Jan;16(1):e32-42. doi: 10.1016/S1470-2045(14)70375-4. Epub 2014 Dec 29.

引用本文的文献

Evaluation of benefit-risk.

Pharmacoeconomics. 2010;28(11):981-6. doi: 10.2165/11537590-000000000-00000.

本文引用的文献

Non-inferiority trials are unethical because they disregard patients' interests.

Lancet. 2007 Dec 1;370(9602):1875-7. doi: 10.1016/S0140-6736(07)61604-3. Epub 2007 Oct 23.

The challenge of managing drug interactions in elderly people.

Lancet. 2007 Jul 14;370(9582):185-191. doi: 10.1016/S0140-6736(07)61092-7.

Appropriate prescribing in elderly people: how well can it be measured and optimised?

Lancet. 2007 Jul 14;370(9582):173-184. doi: 10.1016/S0140-6736(07)61091-5.

Ethical issues in stopping randomized trials early because of apparent benefit.

Ann Intern Med. 2007 Jun 19;146(12):878-81. doi: 10.7326/0003-4819-146-12-200706190-00009.

Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study.

Eur Heart J. 2007 Aug;28(16):1977-83. doi: 10.1093/eurheartj/ehm196. Epub 2007 Jun 13.

Rosiglitazone and cardiovascular risk.

N Engl J Med. 2007 Jun 14;356(24):2522-4. doi: 10.1056/NEJMe078099. Epub 2007 May 21.

Endpoints in studies on myocardial infarction.

Lancet. 2007 Apr 28;369(9571):1430. doi: 10.1016/S0140-6736(07)60667-9.

Composite and surrogate outcomes in randomised controlled trials.

BMJ. 2007 Apr 14;334(7597):756-7. doi: 10.1136/bmj.39176.461227.80.

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.

BMJ. 2007 Apr 14;334(7597):786. doi: 10.1136/bmj.39136.682083.AE. Epub 2007 Apr 2.

Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.

JAMA. 2007 Feb 28;297(8):842-57. doi: 10.1001/jama.297.8.842.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Do we learn the right things from clinical trials?

Eur J Clin Pharmacol. 2008 Feb;64(2):115-25. doi: 10.1007/s00228-007-0411-4. Epub 2008 Jan 29.

Social, cultural and ethical aspects of drug use -- changes over 40 years: a personal look back.

Eur J Clin Pharmacol. 2008 Feb;64(2):107-14. doi: 10.1007/s00228-007-0429-7. Epub 2008 Jan 3.

Historical perspective and evolving concerns for human research.

Cancer Treat Res. 2007;132:1-10. doi: 10.1007/978-0-387-33225-3_1.

The history and development of N-of-1 trials.

J R Soc Med. 2017 Aug;110(8):330-340. doi: 10.1177/0141076817721131.

Show drugs work before selling them.

Nature. 2017 Mar 8;543(7644):174-175. doi: 10.1038/543174a.

Commentary for history special issue of Research Synthesis Methods.

Res Synth Methods. 2015 Sep;6(3):268-71. doi: 10.1002/jrsm.1144. Epub 2015 Jun 10.

Form meets function: A commentary on meta-analytic history.

Res Synth Methods. 2015 Sep;6(3):290-2. doi: 10.1002/jrsm.1141. Epub 2015 Jun 10.

The therapeutic test: an ancient malady in the 21st century.

Ann Pharmacother. 2010 Sep;44(9):1471-7. doi: 10.1345/aph.1P244. Epub 2010 Aug 17.

Seeking medicine for the soul.

R I Med J (2013). 2013 Jul 1;96(7):11-2.

Outcomes and endpoints in trials of cancer treatment: the past, present, and future.

Lancet Oncol. 2015 Jan;16(1):e32-42. doi: 10.1016/S1470-2045(14)70375-4. Epub 2014 Dec 29.

引用本文的文献

Evaluation of benefit-risk.

Pharmacoeconomics. 2010;28(11):981-6. doi: 10.2165/11537590-000000000-00000.

本文引用的文献

Non-inferiority trials are unethical because they disregard patients' interests.

Lancet. 2007 Dec 1;370(9602):1875-7. doi: 10.1016/S0140-6736(07)61604-3. Epub 2007 Oct 23.

The challenge of managing drug interactions in elderly people.

Lancet. 2007 Jul 14;370(9582):185-191. doi: 10.1016/S0140-6736(07)61092-7.

Appropriate prescribing in elderly people: how well can it be measured and optimised?

Lancet. 2007 Jul 14;370(9582):173-184. doi: 10.1016/S0140-6736(07)61091-5.

Ethical issues in stopping randomized trials early because of apparent benefit.

Ann Intern Med. 2007 Jun 19;146(12):878-81. doi: 10.7326/0003-4819-146-12-200706190-00009.

Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study.

Eur Heart J. 2007 Aug;28(16):1977-83. doi: 10.1093/eurheartj/ehm196. Epub 2007 Jun 13.

Rosiglitazone and cardiovascular risk.

N Engl J Med. 2007 Jun 14;356(24):2522-4. doi: 10.1056/NEJMe078099. Epub 2007 May 21.

Endpoints in studies on myocardial infarction.

Lancet. 2007 Apr 28;369(9571):1430. doi: 10.1016/S0140-6736(07)60667-9.

Composite and surrogate outcomes in randomised controlled trials.

BMJ. 2007 Apr 14;334(7597):756-7. doi: 10.1136/bmj.39176.461227.80.

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.

BMJ. 2007 Apr 14;334(7597):786. doi: 10.1136/bmj.39136.682083.AE. Epub 2007 Apr 2.

Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.

JAMA. 2007 Feb 28;297(8):842-57. doi: 10.1001/jama.297.8.842.